NF-kB: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| (6 intermediate revisions by 2 users not shown) | |||
| Line 5: | Line 5: | ||
*'''NF-kB1''' (synthesized as '''p105''' and processed to '''p50''')<br /> | *'''NF-kB1''' (synthesized as '''p105''' and processed to '''p50''')<br /> | ||
*'''NF-kB2''' (synthesized as '''p100''' and processed to '''p52''')<br /> | *'''NF-kB2''' (synthesized as '''p100''' and processed to '''p52''')<br /> | ||
*'''RelA''' (or '''p65''')<br /> | *'''RelA''' (or '''p65''' subunit of NF-kB)<br /> | ||
*'''RelB'''<br /> | *'''RelB'''<br /> | ||
*'''cRel'''. | *'''cRel'''. | ||
See also [[NF-kB (hebrew)]]. | |||
== Relevance == | == Relevance == | ||
NF-kB plays a critical role in cancer development and progression and may determine its response to therapy. NF-kB is a target for chemotherapeutic agents<ref>PMID:16673382</ref>. | NF-kB plays a critical role in cancer development and progression and may determine its response to therapy. NF-kB is a target for chemotherapeutic agents<ref>PMID:16673382</ref>. NF-kB is a critical link between inflammation and cancer<ref>PMID:20066113</ref>. | ||
</StructureSection> | </StructureSection> | ||
| Line 31: | Line 33: | ||
**[[1bfs]] – mp50 dimerization domain<br /> | **[[1bfs]] – mp50 dimerization domain<br /> | ||
**[[1u36]], [[1u3j]], [[1u3y]], [[1u3z]], [[1u41]], [[1u42]] – mp50 dimerization domain (mutant)<br /> | **[[1u36]], [[1u3j]], [[1u3y]], [[1u3z]], [[1u41]], [[1u42]] – mp50 dimerization domain (mutant)<br /> | ||
*NF-kB1 (p52) | |||
**[[7cli]], [[7vup]], [[7vuq]], [[7w7l]] – hp52 + DNA <br /> | |||
*NF-kB1 (p105) | *NF-kB1 (p105) | ||